Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18653610 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | May 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18653655 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | May 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18628353 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | April 2024 | March 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18628366 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | April 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18627708 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18613270 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | March 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18584914 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18486623 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | October 2023 | December 2024 | Allow | 14 | 2 | 0 | No | No |
| 18244500 | METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS | September 2023 | May 2024 | Allow | 8 | 1 | 0 | No | No |
| 18220708 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | July 2023 | December 2023 | Allow | 5 | 0 | 0 | No | No |
| 18340005 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | June 2023 | March 2024 | Allow | 9 | 1 | 0 | No | No |
| 18321159 | USING GENO- OR PHENOTYPING TO ADJUST LSD DOSING | May 2023 | May 2025 | Abandon | 24 | 4 | 0 | Yes | No |
| 18194761 | LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | April 2023 | May 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18295138 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | February 2024 | Allow | 10 | 1 | 0 | No | No |
| 18295146 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18295114 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18295097 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | November 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18194503 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18194496 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18194498 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18194491 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18161633 | BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS | January 2023 | January 2024 | Allow | 12 | 2 | 0 | No | No |
| 18011084 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | December 2022 | May 2023 | Allow | 5 | 0 | 0 | No | No |
| 18081603 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | December 2022 | September 2024 | Allow | 22 | 3 | 0 | No | No |
| 18047188 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | October 2022 | September 2024 | Allow | 23 | 2 | 0 | No | Yes |
| 17902684 | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | September 2022 | March 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17892982 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | August 2022 | December 2022 | Allow | 4 | 1 | 0 | No | No |
| 17891991 | CCL5 Inhibitors | August 2022 | February 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 17877538 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | July 2022 | August 2023 | Allow | 12 | 1 | 1 | No | No |
| 17869896 | USING GENO- OR PHENOTYPING TO ADJUST LSD DOSING | July 2022 | March 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17842389 | TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS | June 2022 | March 2024 | Abandon | 21 | 3 | 0 | Yes | No |
| 17830458 | COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY | June 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17831044 | METHODS OF TREATING NASH | June 2022 | October 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17749748 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | May 2022 | February 2023 | Abandon | 9 | 1 | 0 | No | No |
| 17774489 | ACC INHIBITOR AND USE THEREOF | May 2022 | March 2025 | Allow | 35 | 0 | 0 | No | No |
| 17734581 | USE OF ZINC PORPHYRIN AS AN ANTIMICROBIAL | May 2022 | January 2024 | Allow | 20 | 1 | 0 | No | No |
| 17696723 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury | March 2022 | March 2024 | Allow | 24 | 4 | 1 | Yes | No |
| 17693371 | NOVEL INHIBITORS OF LYSYL OXIDASES | March 2022 | March 2023 | Allow | 12 | 0 | 0 | No | No |
| 17684279 | SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS | March 2022 | February 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17591798 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 37 | 5 | 0 | No | No |
| 17591808 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 37 | 5 | 0 | No | No |
| 17591813 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 38 | 5 | 0 | No | No |
| 17591777 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 37 | 5 | 0 | No | No |
| 17591724 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | February 2025 | Abandon | 36 | 4 | 0 | No | No |
| 17631348 | OXAZEPINONE DERIVATIVE, AGRICULTURAL/HORTICULTURAL INSECTICIDE CONTAINING THE SAME, AND METHOD FOR USING THE SAME | January 2022 | April 2025 | Allow | 38 | 1 | 0 | No | No |
| 17628904 | ORAL GSNOR INHIBITOR AND PHARMACEUTICAL USE THEREOF | January 2022 | March 2023 | Allow | 14 | 1 | 0 | No | No |
| 17580429 | CCL5 Inhibitors | January 2022 | May 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17537663 | ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE | November 2021 | August 2022 | Abandon | 9 | 1 | 0 | No | No |
| 17517796 | METHOD FOR TREATING HYPERTENSION BY USING COMPOUND | November 2021 | December 2023 | Allow | 26 | 1 | 0 | No | No |
| 17492427 | SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER | October 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17486721 | TREPROSTINIL ADMINISTRATION BY INHALATION | September 2021 | April 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17486695 | GERM CELL NUCLEAR FACTOR LIGANDS AND METHODS OF USE THEREOF | September 2021 | June 2025 | Allow | 45 | 2 | 1 | No | No |
| 17479121 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17474203 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL[-BENZAMIDE | September 2021 | December 2024 | Allow | 39 | 2 | 0 | No | No |
| 17471858 | ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17447397 | SOLID DISPERSION FORMULATIONS OF AN FXR AGONIST | September 2021 | May 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17459117 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | August 2021 | January 2025 | Allow | 41 | 1 | 0 | No | No |
| 17411341 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | August 2021 | January 2023 | Allow | 16 | 0 | 0 | No | No |
| 17408285 | METHODS FOR INHIBITING THE PROGRESSION OF NEURODEGENERATIVE DISEASES | August 2021 | June 2022 | Allow | 10 | 1 | 1 | No | No |
| 17406689 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA | August 2021 | January 2022 | Allow | 5 | 0 | 0 | No | No |
| 17403577 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | August 2021 | December 2024 | Allow | 40 | 0 | 0 | No | No |
| 17391869 | COMBINATION THERAPIES | August 2021 | November 2023 | Allow | 28 | 1 | 0 | No | No |
| 17391909 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | August 2021 | March 2022 | Allow | 7 | 1 | 0 | No | No |
| 17380219 | METHODS AND COMPOSITIONS FOR DETECTING PANCREATIC CANCER | July 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17376996 | METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS | July 2021 | October 2023 | Allow | 27 | 1 | 0 | No | No |
| 17373834 | GSNO REDUCTASE INHIBITOR AS AN ADJUNCT THERAPY WITH REMOTE ISCHEMIC CONDITIONING AND THROMBOLYTIC REPERFUSION THERAPIES IN STROKE | July 2021 | December 2021 | Allow | 5 | 1 | 0 | No | No |
| 17372125 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | July 2021 | January 2022 | Allow | 6 | 1 | 0 | No | No |
| 17369203 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | July 2021 | October 2024 | Allow | 40 | 3 | 0 | No | No |
| 17367863 | AZOLE COMOPUND OPHTHALMIC PREPARATION | July 2021 | December 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17366563 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST | July 2021 | November 2023 | Allow | 29 | 1 | 0 | No | No |
| 17338172 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC STROKE | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17330031 | METHODS OF TREATING VIRAL INFECTION USING PROTEASE INHIBITORS | May 2021 | August 2024 | Abandon | 39 | 2 | 0 | No | Yes |
| 17232544 | GSNO REDUCTASE INHIBITOR AS AN ADJUNCT THERAPY IN CEREBRAL THROMBOSIS AND/OR THROMBOEMBOLIC STROKE | April 2021 | December 2021 | Allow | 8 | 1 | 1 | No | No |
| 17280763 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | March 2021 | March 2024 | Allow | 36 | 1 | 1 | No | No |
| 17214309 | TREATMENT OF SKIN LESIONS | March 2021 | October 2023 | Allow | 30 | 1 | 0 | No | No |
| 17210062 | EIF4A INHIBITOR COMBINATIONS | March 2021 | November 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17197561 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | March 2021 | August 2023 | Allow | 29 | 1 | 0 | No | No |
| 17191196 | CCL5 Inhibitors | March 2021 | January 2022 | Allow | 11 | 1 | 0 | Yes | No |
| 17189091 | PHARMACEUTICAL FORMULATION | March 2021 | October 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17269004 | BCL-2 INHIBITORS | February 2021 | August 2024 | Allow | 42 | 2 | 1 | No | No |
| 17169271 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | February 2021 | June 2021 | Allow | 4 | 0 | 1 | No | No |
| 17160009 | Intranasal Compositions For Treatment of Neurological And Neurodegenerative Diseases And Disorders | January 2021 | October 2023 | Allow | 33 | 2 | 0 | No | No |
| 17156387 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | January 2021 | April 2025 | Allow | 50 | 1 | 1 | No | No |
| 17150000 | Compositions And Methods For Modulating Cancer | January 2021 | October 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17149406 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | January 2021 | June 2021 | Allow | 5 | 1 | 0 | No | No |
| 17259828 | COMBINATIONS OF PPAR AGONISTS AND P38 KINASE INHIBITORS FOR PREVENTING OR TREATING FIBROTIC DISEASES | January 2021 | October 2024 | Abandon | 45 | 3 | 0 | No | No |
| 17145515 | Modulators of DUX4 for Regulation of Muscle Function | January 2021 | March 2025 | Abandon | 50 | 3 | 1 | No | No |
| 17144810 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | January 2021 | October 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17136176 | COMPOUND, COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUG | December 2020 | July 2024 | Allow | 42 | 1 | 0 | No | No |
| 17137216 | METHOD FOR AMELIORATION OF INSULIN RESISTANCE | December 2020 | August 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17132743 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | December 2020 | April 2023 | Allow | 28 | 1 | 0 | No | No |
| 17132491 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | December 2020 | April 2023 | Allow | 28 | 1 | 0 | No | No |
| 17254729 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS | December 2020 | September 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17126488 | DRUG FOR PREVENTING AND/OR TREATING DEMENTIA | December 2020 | November 2023 | Allow | 34 | 1 | 0 | No | No |
| 17124640 | METHODS AND COMPOSITIONS FOR TREATING HETEROTOPIC OSSIFICATION | December 2020 | December 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17252469 | Method for Producing Diarylpyridine Derivatives | December 2020 | December 2023 | Allow | 36 | 0 | 0 | No | No |
| 17106348 | METHODS OF TREATING INFLAMMATORY, FIBROTIC, AND PROLIFERATIVE CONDITIONS USING COMPOSITIONS COMPRISING DGLA AND/OR 15-HETRE, AND ASSOCIATED METHODS AND COMPOSITIONS | November 2020 | September 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17103621 | SPIROCYCLIC COMPOUNDS | November 2020 | November 2022 | Allow | 24 | 1 | 1 | No | No |
| 17058105 | USE OF A BISAMIDE DERIVATIVE OF MALONIC ACID FOR TREATING ALLERGIC AND OTHER DISEASES IN HUMANS AND ANIMALS | November 2020 | October 2022 | Allow | 22 | 0 | 0 | No | No |
| 17057384 | COMPOSITION COMPRISING TWO ENZYME INHIBITORS TARGETING TWO DIFFERENT CONFORMATIONS OF AN ENZYME | November 2020 | September 2024 | Abandon | 46 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHMITT, MICHAEL J.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SCHMITT, MICHAEL J works in Art Unit 1629 and has examined 714 patent applications in our dataset. With an allowance rate of 60.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner SCHMITT, MICHAEL J's allowance rate of 60.8% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHMITT, MICHAEL J receive 1.74 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SCHMITT, MICHAEL J is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.4% benefit to allowance rate for applications examined by SCHMITT, MICHAEL J. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 20.8% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.1% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 90.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.9% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 38.2% are granted (fully or in part). This grant rate is in the 35% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.